Nature Reviews Rheumatology

Article	Citations
Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors	595
Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes	423
Mechanisms and therapeutic implications of cellular senescence in osteoarthritis	299
Autoimmune and inflammatory diseases following COVID-19	286
Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment	286
Synovial inflammation in osteoarthritis progression	271
Global epidemiology of systemic lupus erythematosus	246
Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines	242
Emerging pharmaceutical therapies for osteoarthritis	210
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach	199
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021	199
Systemic and organ-specific immune-related manifestations of COVID-19	188
Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications	187
IgG4-related disease: an update on pathophysiology and implications for clinical care	172
The gut–joint axis in rheumatoid arthritis	164
New insights into the role of antinuclear antibodies in systemic lupus erythematosus	149
Toll-like receptor signalling in B cells during systemic lupus erythematosus	145
Early-stage symptomatic osteoarthritis of the knee — time for action	143
Kawasaki disease: pathophysiology and insights from mouse models	143
A new immunometabolic perspective of intervertebral disc degeneration	142
COVID-19 revisiting inflammatory pathways of arthritis	138
Ankylosing spondylitis: an autoimmune or autoinflammatory disease?	136
Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions	135
Immune-mediated necrotizing myopathy: clinical features and pathogenesis	133
Cell-based strategies for IVD repair: clinical progress and translational obstacles	132

Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison	126
Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis	124
Global epidemiology of vasculitis	124
Mechanosignalling in cartilage: an emerging target for the treatment of osteoarthritis	122
Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis	119
The non-coding RNA interactome in joint health and disease	113
Rheumatic disease and COVID-19: epidemiology and outcomes	113
Digital health technologies: opportunities and challenges in rheumatology	110
Revisiting the gut–joint axis: links between gut inflammation and spondyloarthritis	106
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations	106
Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases	106
Epithelial–immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis	105
Oral surveillance and JAK inhibitor safety: the theory of relativity	97
Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases	90
Fibroblast growth factor signalling in osteoarthritis and cartilage repair	86
Cell death in chronic inflammation: breaking the cycle to treat rheumatic disease	78
The endothelium–bone axis in development, homeostasis and bone and joint disease	77
Axial spondyloarthritis: concept, construct, classification and implications for therapy	76
Immune cartography of macrophage activation syndrome in the COVID-19 era	76
TNF in the era of immune checkpoint inhibitors: friend or foe?	76
The evolution of nerve growth factor inhibition in clinical medicine	73
Location, location, location: how the tissue microenvironment affects inflammation in RA	69
Current and future therapies for primary Sjögren syndrome	69
Sex steroids and autoimmune rheumatic diseases: state of the art	66
Global epidemiology of rheumatoid arthritis	64
Targeting interferon-γ in hyperinflammation: opportunities and challenges	61
Interleukin-2 and regulatory T cells in rheumatic diseases	61
Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research	61
Cardiovascular effects of approved drugs for rheumatoid arthritis	58
Treat-to-target in systemic lupus erythematosus: advancing towards its implementation	57
Treatment of axial spondyloarthritis: an update	57
Synovial tissue macrophages in joint homeostasis, rheumatoid arthritis and disease remission	56
Transforming clinical trials in rheumatology: towards patient-centric precision medicine	55
Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica	55
Insights into the biology and therapeutic implications of TNF and regulatory T cells	54
Biological classification of childhood arthritis: roadmap to a molecular nomenclature	54
Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential	53
Lyme arthritis: linking infection, inflammation and autoimmunity	53
Psoriatic arthritis from a mechanistic perspective	52
Why remission is not enough: underlying disease mechanisms in RA that prevent cure	51
The decisive early phase of bone regeneration	51
MIS-C: early lessons from immune profiling	50
IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting	49
Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases	48
Clinical value of DNA methylation markers in autoimmune rheumatic diseases	48
Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care	47
The role of HIF proteins in maintaining the metabolic health of the intervertebral disc	46
Immunogenicity of biologic agents in rheumatology	44
Detection of microvascular changes in systemic sclerosis and other rheumatic diseases	43
Molecular mechanisms of phenotypic variability in monogenic autoinflammatory diseases	42

Interferon lambda in inflammation and autoimmune rheumatic diseases	42
Erosive hand osteoarthritis: latest findings and outlook	41
Disorders of ubiquitylation: unchained inflammation	40
Core and adjunctive interventions for osteoarthritis: efficacy and models for implementation	40
Inflammation and DNA damage: cause, effect or both	40
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis	39
From risk to chronicity: evolution of autoreactive B cell and antibody responses in rheumatoid arthritis	38
Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities	38
Vascular Behçet syndrome: from pathogenesis to treatment	38
Hypertension meets osteoarthritis — revisiting the vascular aetiology hypothesis	37
An introduction to machine learning and analysis of its use in rheumatic diseases	36
Key opinion leaders — a critical perspective	36
Applying precision medicine to unmet clinical needs in psoriatic disease	35
Biomarker development for axial spondyloarthritis	35
Joint distraction for osteoarthritis: clinical evidence and molecular mechanisms	35
Failure of cartilage regeneration: emerging hypotheses and related therapeutic strategies	34
Mechanisms and clinical implications of intervertebral disc calcification	34
The role of neutrophils in rheumatic disease-associated vascular inflammation	34
The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET	33
Cartilage calcification in osteoarthritis: mechanisms and clinical relevance	32
Rheumatic diseases in Africa	31
Sex- and gender-related differences in psoriatic arthritis	31
State-of-the-art evidence in the treatment of systemic sclerosis	30
Matrix metalloproteinases in arthritis: towards precision medicine	29
Acute exacerbation of interstitial lung disease associated with rheumatic disease	28
Importance of lymphocyte–stromal cell interactions in autoimmune and inflammatory rheumatic diseases	27
Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases	26
The role of mitochondria in rheumatic diseases	26
Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases	26
Disease stratification in GCA and PMR: state of the art and future perspectives	26
Joint-on-chip platforms: entering a new era of in vitro models for arthritis	26
How COVID-19 is changing rheumatology clinical practice	25
High risk of autoimmune diseases after COVID-19	25
Differentiating between UCTD and early-stage SLE: from definitions to clinical approach	25
Emotion regulation and the salience network: a hypothetical integrative model of fibromyalgia	25
Immunological memory in rheumatic inflammation — a roadblock to tolerance induction	25
Intervertebral disc degeneration and osteoarthritis: a common molecular disease spectrum	25
Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study	25
Studying osteoarthritis with artificial intelligence applied to magnetic resonance imaging	24
Rheumatoid sarcopenia: loss of skeletal muscle strength and mass in rheumatoid arthritis	24
Genetics of ANCA-associated vasculitis: role in pathogenesis, classification and management	24
Emerging concepts of type I interferons in SLE pathogenesis and therapy	23
Genetics and epigenetics of primary Sjögren syndrome: implications for future therapies	23
Treatment of lupus nephritis: consensus, evidence and perspectives	23
Regulation of activated T cell survival in rheumatic autoimmune diseases	23
Treat-to-target in axial spondyloarthritis — what about physical function and activity?	23
Cellular metabolic adaptations in rheumatoid arthritis and their therapeutic implications	22
Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease	22
Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis	22
Glycobiology of rheumatic diseases	22
Adopting PROs in virtual and outpatient management of RA	22
Challenges in the management of older patients with inflammatory rheumatic diseases	21
Endothelial function and endothelial progenitor cells in systemic lupus erythematosus	21
Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need	20
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	19
Precision medicine: the precision gap in rheumatic disease	17
Precision medicine in systemic lupus erythematosus	17
Machine learning in precision medicine: lessons to learn	16
Busting the myth of methotrexate chronic hepatotoxicity	15
Targeting calcium-related mechanotransduction in early OA	15
JAK inhibitors and VTE risk: how concerned should we be?	14
Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis	13
New insights into the treatment of CTD-ILD	13
Involvement of the secosteroid vitamin D in autoimmune rheumatic diseases and COVID-19	12
Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone	12
Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management	12
Genome editing to define the function of risk loci and variants in rheumatic disease	11
TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond	11
Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care	11
Mapping the musculoskeletal system one cell at a time	11
Age-related mechanisms in the context of rheumatic disease	10
Evolving concepts in systemic lupus erythematosus damage assessment	10
When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy	10
Assessment of disease outcome measures in systemic sclerosis	10
Revisiting the cardiovascular risk of hydroxychloroquine in RA	9
Critical appraisal of serum urate targets in the management of gout	9
Spectrum and impact of checkpoint inhibitor-induced irAEs	9
Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies	8
New insights into RA genetics from GWAS meta-analysis	8
Striking a balance in rheumatoid arthritis prevention trials	8

The bone marrow side of axial spondyloarthritis	8
The road to equity for women in academic rheumatology	8
Skin–kidney crosstalk in SLE	7
HIPPOCRATES: improving diagnosis and outcomes in psoriatic arthritis	7
Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy	7
Does psoriasis treatment affect PsA development?	7
Hydroxychloroquine dose: balancing toxicity and SLE flare risk	7
The Musculoskeletal Knowledge Portal: improving access to multi-omics data	7
Synovial macrophage populations linked to RA remission	7
New refinements aim to optimize articular cartilage tissue engineering	6
Osteocyte death promotes bone loss	6
Author Correction: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021	6
Biological and clinical roles of IL-18 in inflammatory diseases	6
Kawasaki disease and MIS-C share a host immune response	6
Rheumatoid arthritis prevention in arthralgia: fantasy or reality?	6
NETs directly injure cartilage in RA	6
IL-17A and IL-17F in tissue homeostasis, inflammation and regeneration	6
The (Orf)ull truth about IRF5 and type I interferons in SLE	6
Linking cell mechanobiology and inflammation in IVD degeneration	6
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	6
Therapeutic potential in rheumatic diseases of extracellular vesicles derived from mesenchymal stromal cells	6
Somatic mutations cause VEXAS syndrome	6